PeptidePedia The community reference

Talk:Retatrutide

Discussion page·3 threads·no archives

This article is within the scope of the pharmacology working group.
Tagged {{update}} pending phase 3 publication.

This is the discussion page for the article Retatrutide. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Phase 2 figures in the leadResolved

−24.2% in the second paragraph of the lead is going to be quoted everywhere. The caveat that this is phase 2 needs to be in the same sentence, not the next one. — PreregPriya (talk) 09:25, 2 March 2026 (UTC)

Restructured so the sentence carries both the figure and the phase, and the following sentence explains why phase 2 effect sizes shrink. — RetatrutideRuben (talk) 12:40, 2 March 2026 (UTC)

Better. The plateau observation is genuinely interesting and I would keep it, but it is in the results section where it belongs rather than the lead. ✓ Done — PreregPriya (talk) 08:10, 3 March 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

No reference standard — is that claim safe?

The last section says there is no generally available reference standard. Is that verifiable, or is it an inference from the absence of an approved product? — PrimarySrcPatia (talk) 10:48, 9 May 2026 (UTC)

It is an inference, and a defensible one — compendial standards follow monographs and there is no monograph for an unapproved molecule. I have reworded to "no reference standard generally available" rather than asserting none exists anywhere. — Chromatokid (talk) 14:22, 9 May 2026 (UTC)

That wording is fine. It says what can be observed rather than what is true of the world. — AttributeAnders (talk) 09:05, 10 May 2026 (UTC)

Heart-rate signal deserves more space

The dose-dependent heart-rate increase is the most distinctive safety observation in this programme and gets two sentences. Given it is attributable to the glucagon component, it seems worth a subsection. — SafetySignalSid (talk) 11:15, 17 June 2026 (UTC)

I would rather expand it when phase 3 numbers exist than build a subsection around phase 2 figures. Noting the request here so it is not lost. — RetatrutideRuben (talk) 15:33, 17 June 2026 (UTC)

This page was last edited on 17 June 2026, by RetatrutideRuben. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).